Life Science Nation Newsletter  | August 18,  2016  |  Issue 175

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Aug. 11  - Aug. 17)
Seeks Early Stage Therapeutic Platforms and Devices in Eye Diseases
Invests In Series A Rounds In Genomics
Seeks 510k Devices
Seeks Therapeutic, Diagnostics and Med Device Deals in US and Europe
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI Landing on MaRS

RESI on MaRS Investors Panel

By Dennis Ford, CEO of LSN; Creator of RESI Conference Series

As RESI comes back to Boston for its 10th conference, we're excited to announce the early stage life science companies that will be participating in the event's RESI Innovation Challenge.

The 30 participating companies have been hand-selected by LSN's scientific review committee based on the innovative nature of their core technology and how well-positioned each is to capitalize on their respective market opportunities. The selected companies, two thirds of which have received funding from various NIH institutes, cover all corners of the life science domain including therapeutics, medtech, diagnostics and digital health...


Technology Platform




Medical Device

Digital Health